Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

POLICY POINTS: Regulatory agencies may have limited evidence on the clinical benefits and harms of new drugs when deciding whether new therapeutic agents are allowed to enter the market and under which conditions, including whether approval is granted under special regulatory pathways and obligation...

Descripción completa

Detalles Bibliográficos
Autores principales: SALCHER‐KONRAD, MAXIMILIAN, NACI, HUSEYIN, DAVIS, COURTNEY
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Scholarship
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772660/
https://www.ncbi.nlm.nih.gov/pubmed/33021339
http://dx.doi.org/10.1111/1468-0009.12476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772660/
https://www.ncbi.nlm.nih.gov/pubmed/33021339
http://dx.doi.org/10.1111/1468-0009.12476

Ejemplares similares